(Q35123246)

6 August 2017

1 reference

title

The natural history of prostate cancer (English)

1 reference

6 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0094-0143(02)00182-9

31 December 2023

author name string

Brian Kessler

series ordinal

1

1 reference

6 August 2017

Peter Albertsen

series ordinal

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12735499

31 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0094014302001829?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0094-0143(02)00182-9

https://api.elsevier.com/content/article/PII:S0094014302001829?httpAccept=text/plain

31 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1016/S0094-0143(02)00182-9

Urologic Clinics of North America

31 December 2023

published in

1 reference

6 August 2017

30

1 reference

6 August 2017

219-226

1 reference

6 August 2017

2

1 reference

6 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

The role of increasing detection in the rising incidence of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Survival with conservative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

High 10-year survival rate in patients with early, untreated prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Natural history of localised prostatic cancer. A population-based study in 223 untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Population-based study of long-term survival in patients with clinically localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

The impact of co-morbidity on life expectancy among men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

The Importance of Co-existent Disease in the Occurrence of Postoperative Complications and One-Year Recovery in Patients Undergoing Total Hip Replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Are increasing 5-year survival rates evidence of success against cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900182-9

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference